Metastatic Colorectal Carcinoma Clinical Trial
Official title:
Analysis of the Efficacy of Local Liver Treatment for Multi-organ Colorectal Cancer Metastases: A Prospective, Multicenter, Non-randomized Concurrent Controlled Study
The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer, whether it can benefit the prognosis and explore the risk factors related to the prognosis.
Primary objective: 1.To determine the survival benefit of local radical resection of liver metastases in patients with resectable liver and controllable extrahepatic metastases from colorectal cancer. Secondary objectives: 1. To explore the prognosis-related risk factors in patients with colorectal cancer liver metastases combined with extrahepatic metastases 2. To assess patients' quality-of-life in each treatment group with questionnaires. 3. To evaluate the safety of the treatment in each treatment group. Grouping Method: Patients are assigned to 1 of 2 groups according to their willingness. GROUP I: Patients undergo radical local treatment of liver metastases (hepatectomy, ablation) combined with systemic therapy. GROUP II: Patients receive Systemic therapy only or combined local interventions (TACE, HAIC) Patients are followed up every 3 months up to 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04673955 -
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
|
||
| Active, not recruiting |
NCT04164069 -
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
|
Phase 1 | |
| Active, not recruiting |
NCT03981614 -
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05863195 -
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
|
Phase 3 | |
| Recruiting |
NCT04599140 -
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05803382 -
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03337087 -
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06115174 -
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer
|
Phase 4 | |
| Active, not recruiting |
NCT04362839 -
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02738606 -
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
|
Phase 2 | |
| Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04693377 -
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
|
N/A | |
| Recruiting |
NCT06265285 -
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
|
Phase 2 | |
| Recruiting |
NCT06269978 -
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06147037 -
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
|
Phase 1 | |
| Active, not recruiting |
NCT02873195 -
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02595931 -
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Active, not recruiting |
NCT03993327 -
An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer
|
Phase 1 | |
| Recruiting |
NCT05322590 -
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05759923 -
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
|
Phase 1 |